Metabolic risk factor targets in relation to clinical characteristics and comorbidities among individuals with type 2 diabetes treated in primary care – The countrywide cross‐sectional AUSTRO ‐ PROFIT study
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.15988 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Harald Sourij und 16 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Metabolic Medicine Trials Unit, Medical University of Graz, Graz, Austria. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Primary Health Care, Comorbidity, Glycated Hemoglobin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk Foundation Center for Basic Metabolic Research, Roche Diagnostics, MSD Sharp and Dohme.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims This study assessed the achievement rates of metabolic risk factor targets and their association with clinical characteristics and comorbidities among individuals with type 2 diabetes (T2D) treated in the primary care in Austria. Materials and Methods A countrywide cross‐sectional study, the AUSTRO‐PROFIT, was conducted in Austria from 2021 to 2023 on 635 individuals with T2D. Metabolic risk factor targets were defined as the percentage of people achieving low‐density lipoprotein cholesterol (LDL‐C)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Interdisciplinary Metabolic Medicine Trials Unit, Medical University of Graz, Graz, Austria.
- Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
- Division of Cardiology, Medical University of Graz, Graz, Austria.
- Division of Endocrinology, Rheumatology and Acute Geriatrics, Clinic Ottakring, Vienna, Austria.
- Clinical Division of Internal Medicine, Saint John of God Hospital, Linz, Austria.
- Department of Internal Medicine and Karl Landsteiner Institute of Obesity and Metabolic Disorders, Landstrasse Clinic, Vienna, Austria.
ORCID-Profile: Harald Sourij, Kehkishan Azhar, Faisal Aziz, Julia K Mader, Norbert J Tripolt
Förderung
- Novo Nordisk Foundation Center for Basic Metabolic Research
- Roche Diagnostics
- MSD Sharp and Dohme
- Novartis Pharma
- Daiichi Sankyo Europe
- Österreichische Diabetes Gesellschaft
- Boehringer Ingelheim
Zitieren
APA
Sourij, H., Azhar, K., Aziz, F., Kojzar, H., Sourij, C., Fasching, P., Clodi, M., Ludvik, B., Mader, J. K., Resl, M., Rega-Kaun, G., Ress, C., Stechemesser, L., Stingl, H., Tripolt, N. J., Wascher, T., & Kaser, S. (2025). Metabolic risk factor targets in relation to clinical characteristics and comorbidities among individuals with type 2 diabetes treated in primary care – The countrywide cross‐sectional AUSTRO ‐ PROFIT study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15988
Vancouver
Sourij H, Azhar K, Aziz F, Kojzar H, Sourij C, Fasching P, et al. Metabolic risk factor targets in relation to clinical characteristics and comorbidities among individuals with type 2 diabetes treated in primary care – The countrywide cross‐sectional AUSTRO ‐ PROFIT study. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.15988
BibTeX
@article{Sourij2025,
author = {Sourij, Harald and Azhar, Kehkishan and Aziz, Faisal and Kojzar, Harald and Sourij, Caren and Fasching, Peter and Clodi, Martin and Ludvik, Bernhard and Mader, Julia K and Resl, Michael and Rega-Kaun, Gersina and Ress, Claudia and Stechemesser, Lars and Stingl, Harald and Tripolt, Norbert J and Wascher, Thomas and Kaser, Susanne},
title = {Metabolic risk factor targets in relation to clinical characteristics and comorbidities among individuals with type 2 diabetes treated in primary care – The countrywide cross‐sectional AUSTRO ‐ PROFIT study},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.15988}
}
EUVIMED